Brainomix E-Lung Analysis Detects Treatment Effects in Phase 2a IPF Trial

Brainomix and Endeavor BioMedicines reported that Brainomix's AI-powered e-Lung tool detected significant treatment effects of taladegib in a Phase 2a idiopathic pulmonary fibrosis trial by analyzing CT scans. The AI analysis revealed improvements in lung volume, fibrosis extent, and disease burden, supporting its use for sensitive, objective endpoints in clinical trials.